SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class of specific proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.
Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow
and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer
Center in New York, and Ravi Vij, M.D., Associate Professor of Medicine,
Division of Oncology, Section of Bone Marrow Transplantation at
Activity in Relapsed and Refractory Multiple Myeloma Patients
Dr. Jagannath presented data from an ongoing, open-label, multi-center study of single-agent carfilzomib in multiple myeloma patients. All patients in this trial were refractory to their last treatment. Of 39 evaluable patients, ten (26%) achieved partial or minor responses and an additional 16 (41%) achieved stable disease. Importantly, responses have also been durable with median treatment duration of 240 days, or approximately eight months.
"Patients enrolled in this Phase 2 trial have previously failed
bortezomib, lenalidomide, thalidomide, and stem cell transplant. Carfilzomib
as a single-agent is well tolerated and has demonstrated encouraging
|SOURCE Proteolix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved